Dr Etienne De Braekeleer talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about metabolic vulnerabilities that exist within NOTCH-driven T cell acute lymphoblastic leukaemia (ALL).
He explains the importance of using genome-wide CRISPR screens to identify new targets for relapsed and refractory ALL and more specifically, NOTCH-driven T-cell ALL.
Dr De Braekeleer discusses the role of NADK in this pathway and future efforts should be focused on elucidating the relationship between NOTCH and reduced ROS levels in ALL.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.